Vincent Rajkumar: All the drug approvals for relapsed multiple myeloma in 20 years
Tina Crosbie, Hematology Pharmacist at The Ottawa Hospital and at Extend Pharmacy, shared a post by Vincent Rajkumar, Editor-in-Chief of Blood Cancer Journal on X, adding:
“Great list of FDA approvals in relapsed Multiple Myeloma. A hot topic this year at Canadian Association of Pharmacy in Oncology (CAPhO) conference to share, clinical pearls.”
Quoting Vincent Rajkumar’s post:
“Here are all the drug approvals for relapsed multiple myeloma in 20 years. Bookmark it! Amazing!
Guidelines on how to use these drugs in each stage of the myeloma. One stop resource for estimating prognosis, duration of response and survival. Our one stop website for myeloma risk:
- Multiple Myeloma risk stratification -SMM risk stratification.
- MGUS risk stratification.
- AL amyloid risk stratification.
New:
- IFM Frailty score.
- Waldenstrom prognosis.
- iSTOP MM guide for marrow in MGUS.
Concise review on treatment of myeloma. I’m working on an update for this year.”
Source: Tina Crosbie/X and Vincent Rajkumar/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023